MacroGenics, Inc.

MacroGenics, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative, next-generation antibody-based therapeutics primarily for the treatment of cancer, with additional applications in autoimmune disorders and infectious diseases. Headquartered in Rockville, Maryland, the company focuses on improving the lives of cancer patients through its advanced research and development efforts.

The company leverages proprietary technology platforms to generate a diverse pipeline of product candidates, including antibody-drug conjugates (ADCs) and multi-specific antibodies, such as its DART and TRIDENT molecules. Key proprietary product candidates in clinical development include lorigerlimab, a bispecific PD-1 x CTLA-4 DART molecule; MGC026, a B7-H3-targeting ADC; and MGC028, an ADAM9-targeting ADC. MacroGenics has also developed three FDA-approved therapies—ZYNYZ, MARGENZA, and TZIELD—which are out-licensed or sold to global biopharmaceutical partners.

In recent leadership changes, Eric Risser was appointed President and Chief Executive Officer in August 2025, succeeding Scott Koenig. The company has also engaged in strategic financial activities, including a royalty purchase agreement with Sagard Healthcare Partners for its drug ZYNYZ, which provided an upfront sum of $70 million to extend its cash runway. Additionally, MacroGenics sold its GMP manufacturing facility to Bora in a $122 million deal. The company continues to advance its pipeline, with recent news including the FDA lifting a clinical hold on a gynecological cancer treatment trial in April 2026, following a prior study pause due to safety concerns.